Overview

Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
A single dose, two treatments (two cephalexin capsules brands), two sequences, cross-over design was used with a washout of 7 days between the two study periods. Treatment groups balanced with the same number of healthy volunteers who were randomly (in two strata: male and female) assigned to the study drug administration sequences.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Collaborator:
Corporación Bonima S.A. de C.V.
Treatments:
Cephalexin